Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE collaboration): a meta-analysis of genome-wide association studies.
Traylor M., Farrall M., Holliday EG., Sudlow C., Hopewell JC., Cheng YC., Fornage M., Ikram MA., Malik R., Bevan S., Thorsteinsdottir U., Nalls MA., Longstreth W., Wiggins KL., Yadav S., Parati EA., Destefano AL., Worrall BB., Kittner SJ., Khan MS., Reiner AP., Helgadottir A., Achterberg S., Fernandez-Cadenas I., Abboud S., Schmidt R., Walters M., Chen WM., Ringelstein EB., O'Donnell M., Ho WK., Pera J., Lemmens R., Norrving B., Higgins P., Benn M., Sale M., Kuhlenbäumer G., Doney AS., Vicente AM., Delavaran H., Algra A., Davies G., Oliveira SA., Palmer CN., Deary I., Schmidt H., Pandolfo M., Montaner J., Carty C., de Bakker PI., Kostulas K., Ferro JM., van Zuydam NR., Valdimarsson E., Nordestgaard BG., Lindgren A., Thijs V., Slowik A., Saleheen D., Paré G., Berger K., Thorleifsson G., Australian Stroke Genetics Collaborative, Wellcome Trust Case Control Consortium 2 (WTCCC2) None., Hofman A., Mosley TH., Mitchell BD., Furie K., Clarke R., Levi C., Seshadri S., Gschwendtner A., Boncoraglio GB., Sharma P., Bis JC., Gretarsdottir S., Psaty BM., Rothwell PM., Rosand J., Meschia JF., Stefansson K., Dichgans M., Markus HS., International Stroke Genetics Consortium None.
BACKGROUND: Various genome-wide association studies (GWAS) have been done in ischaemic stroke, identifying a few loci associated with the disease, but sample sizes have been 3500 cases or less. We established the METASTROKE collaboration with the aim of validating associations from previous GWAS and identifying novel genetic associations through meta-analysis of GWAS datasets for ischaemic stroke and its subtypes. METHODS: We meta-analysed data from 15 ischaemic stroke cohorts with a total of 12 389 individuals with ischaemic stroke and 62 004 controls, all of European ancestry. For the associations reaching genome-wide significance in METASTROKE, we did a further analysis, conditioning on the lead single nucleotide polymorphism in every associated region. Replication of novel suggestive signals was done in 13 347 cases and 29 083 controls. FINDINGS: We verified previous associations for cardioembolic stroke near PITX2 (p=2·8×10(-16)) and ZFHX3 (p=2·28×10(-8)), and for large-vessel stroke at a 9p21 locus (p=3·32×10(-5)) and HDAC9 (p=2·03×10(-12)). Additionally, we verified that all associations were subtype specific. Conditional analysis in the three regions for which the associations reached genome-wide significance (PITX2, ZFHX3, and HDAC9) indicated that all the signal in each region could be attributed to one risk haplotype. We also identified 12 potentially novel loci at p<5×10(-6). However, we were unable to replicate any of these novel associations in the replication cohort. INTERPRETATION: Our results show that, although genetic variants can be detected in patients with ischaemic stroke when compared with controls, all associations we were able to confirm are specific to a stroke subtype. This finding has two implications. First, to maximise success of genetic studies in ischaemic stroke, detailed stroke subtyping is required. Second, different genetic pathophysiological mechanisms seem to be associated with different stroke subtypes. FUNDING: Wellcome Trust, UK Medical Research Council (MRC), Australian National and Medical Health Research Council, National Institutes of Health (NIH) including National Heart, Lung and Blood Institute (NHLBI), the National Institute on Aging (NIA), the National Human Genome Research Institute (NHGRI), and the National Institute of Neurological Disorders and Stroke (NINDS).